To further disclose the antitumor mechanism of VGB4, the immunohistochemical markers CD31, CD34, Ki-67, Bcl2, P53, p-VEGFR1 and p-VEGFR2 were examined in tumor tissues in each group on the last day of the peptide administration (day 28). This evidence concerns the gene TP53 and neoplasm.